← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Eutropics Pharmaceuticals, Inc.
Dorchester, MA
$8,701,768
Total funding
7
Grants
Funding over time
peak $1.7M · FY2008–19$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,701,768 · 7
By mechanism
R44$4,975,544 · 2
N44$2,999,489 · 2
N43$399,752 · 2
R43$326,983 · 1
Investigators at Eutropics Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FO$1,499,746
N44 · FY2012 · CA
IGF::CT::IGF DEVELOPMENT OF PRAEDICARE DX AS CDX FOR AMLPERIOD OF PERFORMANCE: SEPTEMBER 19, 2014 THROUGH SEPTEMBER 18, 2015$1,499,743
N44 · FY2014 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments$1,000,000
R44 · FY2019 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments$998,807
R44 · FY2017 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments$991,179
R44 · FY2018 · CA
Development of small molecule inhibitor of Mcl-1 for cancer treatment$971,831
R44 · FY2011 · CA
Development of small molecule inhibitor of Mcl-1 for cancer treatment$691,769
R44 · FY2010 · CA
Development of small molecule inhibitors of Mcl-1 for cancer treament$326,983
R43 · FY2008 · CA
Development of small molecule inhibitor of Mcl-1 for cancer treatment$321,958
R44 · FY2011 · CA
OTHER FUNCTIONS R&D- BIOMEDICAL (BASIC RESEARCH)$199,892
N43 · FY2012 · CA
BH3 Profiling as a Companion Diagnostic For Velcade$199,860
N43 · FY2010 · CA